Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer?s Disease and Parkinson?s Disease from Pfizer Inc.
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases
- Biogen to pay Pfizer $75 million upfront plus potential milestones of up to $635 million, and royalties
- PF-05251749 complements the Company?s pipeline of potential disease-modifying therapies for Alzheimer?s and Parkinson?s diseases